JWH-122

JWH-122 is a synthetic cannabinoid that is derived from naphthoylindole. It acts as a full agonist at both the CB1 and CB2 cannabinoid receptors, with a binding affinity of 0.69nM at CB1 and 1.2nM at CB2.

Chemistry

JWH-122 is a part of the JWH series of synthetic cannabinoids. It is structurally related to JWH-018, with the only difference being the addition of a methyl group to the 4 position of the naphthoyl ring. This modification increases the potency of JWH-122 by approximately 5 times compared to JWH-018.

Pharmacology

JWH-122 acts as a full agonist at both the CB1 and CB2 cannabinoid receptors. The CB1 receptor is primarily located in the brain, and is responsible for the psychoactive effects of cannabinoids. The CB2 receptor is primarily located in the immune system, and is responsible for the immunomodulatory effects of cannabinoids.

Effects

The effects of JWH-122 are similar to those of other synthetic cannabinoids and include euphoria, relaxation, perceptual alterations, and cognitive impairment. However, JWH-122 is more potent than many other synthetic cannabinoids, and its use has been associated with a number of adverse effects including anxiety, paranoia, tachycardia, and seizures.

Legal status

JWH-122 is illegal in many countries, including the United States, where it is classified as a Schedule I controlled substance.

See also

• JWH-018
• JWH-073
• JWH-200
• Synthetic cannabinoids
• Cannabinoid receptor

JWH-122 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia